IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
IGM Biosciences was founded in 2011 in Seattle, WA with a mission to develop novel immunotherapies for the treatment of cancer and autoimmune diseases. The company acquired medicinal chemistry, pharmaceutical, and biopharmaceutical development capabilities in 2013 to build a robust pipeline of innovative therapeutic agents. In 2016, IGM secured a research collaboration with Roche and in 2018 the company commenced its first clinical trial. Today, the company is focused on developing a broad array of next-generation immuno-oncology therapies, while expanding its pipeline of therapeutic modalities.
Our mission is to develop a new era of powerful therapeutics that leverage the natural power of the human immune system to fight cancer and autoimmune diseases.
Our vision is to be a globally recognized leader in the development of next-generation immunotherapies that can improve the lives of patients around the world.
Mr. Misbah Tahir (Chief Financial Officer)
Mr. Steven Weber (SVP, Corp. Controller & Principal Accounting Officer)
Dr. Bruce A. Keyt (Chief Scientific Officer)
Mr. Paul C. Graffagnino (VP of Legal Affairs)
Ms. Suzette Tauber (Chief HR Officer)
Dr. Shinyu Chen M.D., Ph.D. (Consultant)
Dr. Angus M. Sinclair Ph.D. (Sr. VP of Immuno-Oncology)
Recognition and Awards
IGM has received numerous awards throughout its history, most notably the Frost & Sullivan Best Practices Award for Technological Leadership in 2018 and the Deloitte Technology Fast 500 Award in 2016. In addition, IGM has been recognized for its dedication to environmental, social, and economic sustainability.